Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
